VivoSim Labs Receives New Nasdaq Delisting Notice for Bid Price Deficiency

summarizeSummary

VivoSim Labs received a new Nasdaq delisting notice for failing the $1 minimum bid price rule, with a compliance deadline of February 16, 2027. The company intends to use a reverse stock split, pending stockholder approval at the September 30 meeting, to regain compliance.

check_boxKey Events · Legal and Risk Events · VIVS

• New Nasdaq Bid Price Deficiency

  On August 17, 2026, VivoSim received a Nasdaq notice that its stock closed below $1 for 30 consecutive business days, violating Rule 5550(a)(2).

• 180-Day Compliance Window

  The company has until February 16, 2027 to regain compliance by maintaining a closing bid price of at least $1 for 10 consecutive business days, with a possible 180-day extension.

• Reverse Split as Remedy

  VivoSim plans to effect a reverse stock split (1-for-5 to 1-for-20) to lift the share price above $1, subject to stockholder approval at the September 30, 2026 annual meeting.

• Distinct from Prior Equity Notice

  This bid price deficiency is separate from the July 24, 2026 notice for the $2.5M stockholders' equity requirement, which the company announced it had cured on August 6, 2026.

auto_awesomeAnalysis · VIVS · Life Sciences

VivoSim Labs received a new Nasdaq delisting notice on August 17, 2026, this time for failing the $1 minimum bid price requirement. The stock has traded below $1 for 30 consecutive business days, triggering a 180-day compliance period ending February 16, 2027. This is a separate deficiency from the July 24 equity shortfall, which the company had announced it cured on August 6. The company plans to pursue a reverse stock split, already proposed in its proxy for the September 30 annual meeting, to regain compliance. While the notice has no immediate effect on trading, it adds fresh delisting risk and underscores the urgency of the reverse split vote.